FDA Approves HYDROMORPHONE HYDROCHLORIDE — Ascent Pharmaceuticals Inc

Ascent Pharmaceuticals Inc. received FDA approval for the ANDA210506 of Hydromorphone Hydrochloride Tablets, offering a potential additional oral generic option in the high-volume opioid analgesic market. The launch will intensify competitive pricing pressures on existing branded and generic competitors, potentially reducing the average generic market share held by competitors like Mallinckrodt.